Activity

98dupC).

We reported a novel mild phenotype of LGMD2Y with relatively selective distal upper limb weakness and joint contracture and revealed the heterogeneity of LGDM2Y and the role of the LAP1 isoform by literature review.

We reported a novel mild phenotype of LGMD2Y with relatively selective distal upper limb weakness and joint contracture and revealed the heterogeneity of LGDM2Y and the role of the LAP1 isoform by literature review.

Digital health tools (WeChat or mobile health apps) provide opportunities for new methods of hypertension management for hypertensive patients. However, the willingness of these patients to use social media and mobile health apps for hypertension management remains unclear. This study explored the characteristics and requirements of patients willing to use digital health (WDH) tools to manage hypertension.

From February to March 2018, we administered questionnaires to 1089 patients with hypertension at eight Chinese primary medical units. We assessed independent risk factors of WDH and requirement among WDH patients.

Overall, 43% (465/1089) of participants were WDH patients, who were younger (58 ± 12 vs 61 ± 13 years) and had a greater proportion of employed individuals (31% vs 14%) and higher education levels (65% vs 52%) than the non-WDH patients (all P < 0.0001). After adjusting for other risk factors, higher education (OR 0.52; 95% CI 0.34-0.79), good medicine adherence (OR 1.5; 95% CI 1.0-2.3) ance and blood pressure self-monitoring. Digital health tool developers and researchers should pay particular attention to recruiting older, less educated and unemployed patients with less willingness and who are less technologically savvy and research the requirements of WDH patients (blood pressure monitoring, medication reminders, and knowledge education) in the future.

Students, staff, and faculties are involved in activities that exposed them to a range of minor to severe or even fatal accidents in academic settings. Managing work environment risks is crucial to any safety and health prevention program. This study developed a risk assessment using combinations of hazards and risk factors to establish a scale of measures in a risk reduction action plan.

This cross-sectional study was conducted in an Iranian medical sciences university in 2018. A structured method of risk assessment was developed, applying a three-step procedure to identify hazards, consequences, and risk evaluation. Data were collected through detailed health, safety, and environment checklist in 38 different sites. Finally, the risks quantified, prioritized, and control measures proposed accordingly. Chi-square and correlation tests assessed how environmental factors were associated with hazard consequences. VT104 molecular weight The analysis results were evaluated at the significance level of 0.05.

The frequencies of mods and activities. Universities should provide training in risk reduction programs to increase the awareness of students, staff, and faculties, which can improve life safety in a university environment.

The impact of work-related musculoskeletal symptoms (WMSS) permeates various occupations.

To compare WMSS and associated risk factors among domestic gas workers (DGWs) and staff of Works Department (SWD) in Enugu.

One-hundred adults (DGW = 50, SWD = 50) participated in this cross-sectional study. The Nordic Musculoskeletal Questionnaire and a demographics questionnaire were used to assess the prevalence of WMSS and related risk factors. Data were analysed using independent t-test or Mann-Whitney U, chi-square, and logistic regression at p < 0.05.

The DGWs (86%) had a significantly (χ2 = 24.45, p < 0.001) higher WMSS than the SWD (38%). Lower-back (54%) and shoulder (52%) were the most affected body parts among the DGWs in comparison to the hips/thighs (20%) among the SWD. Work-related factors such as daily work-duration (χ2 = 75.44, p < 0.001), lifting training (χ2 = 96.24, p <0.001), and use of personal protective equipment (PPE) of facemask (χ2 = 100.0, p <0.001) and gloves (χ2 = 96.0ng beyond 8 h per day, sleeping less than 6 h per day, and insufficient exercise increase the risks of WMSDs, especially among the DGWs. To mitigate the adverse effects of WMSDs, SWD and DGWs require break and leave periods, PPE and assistive devices, exercise, medical check-up, and workplace ergonomics.

Phase 3 studies suggest that induction chemotherapy (ICT) of cisplatin and 5-fluorouracil plus docetaxel (TPF) is effective but toxic for patients with squamous-cell carcinoma of the head and neck (SCCHN). Dose-dense chemotherapy may yield favorable outcomes compared with standard-dose chemotherapy, yet the optimal induction regimen remains undefined. We assessed the efficacy and tolerability of biweekly dose-dense TPF ICT in patients with SCCHN.

In this prospective phase II study, We enrolled patients with stage III/IV (AJCC 7th edition) unresectable squamous cell carcinoma of head and neck cancer. Patients received dose-dense TPF (ddTPF) with cisplatin and docetaxel 50 mg/m2 on day 1, leucovorin 250 mg/m2 on day1, followed by 48-h continuous infusion of 2500 mg/m2 of 5-fluorouracil on day 1 and 2, every 2 weeks for 6 cycles followed by radiotherapy. The primary endpoint was the response rate (RR) after ICT.

Fifty-eight patients were enrolled from June 2014 to September 2015. Overall RR after ICT was 89.6% [complete response (CR), 31%; partial response (PR), 58.6%]. Grade 3/4 neutropenia, mucositis, and diarrhea incidences were 25.9, 1.7, and 1.7%, respectively. 94.8% of patients completed all treatment courses of ICT without dose reduction. The 3-year overall survival (OS) was 54.3% (95%CI 39.7 to 66.8%) and progression-free survival (PFS) was 34.3% (95%CI 22.0 to 46.9%). Multivariate analysis showed that CR after ICT is an independent prognostic factor for OS and PFS.

Six cycles of ddTPF is an active, well-tolerated induction regimen for patients with SCCHN. The presence of CR after ICT predicted long-term survival.

ClinicalTrials.gov Identifier NCT04397341 , May 21, 2020, retrospectively registered.

ClinicalTrials.gov Identifier NCT04397341 , May 21, 2020, retrospectively registered.